Detected substances among patients with confirmed bromazolam exposure who present to the emergency department following a suspected opioid and/or stimulant-related non-fatal overdose
Alyssa M. Falise , Amanda Sutphin , Rachel Culbreth , Kim Aldy , Keith Burkhart , Jeffrey Brent , Sharan L. Campleman , Hannah Day , Aprielle Wills , Alex Krotulski , Paul Wax , On Behalf of the ToxIC DOTS Study Group
{"title":"Detected substances among patients with confirmed bromazolam exposure who present to the emergency department following a suspected opioid and/or stimulant-related non-fatal overdose","authors":"Alyssa M. Falise , Amanda Sutphin , Rachel Culbreth , Kim Aldy , Keith Burkhart , Jeffrey Brent , Sharan L. Campleman , Hannah Day , Aprielle Wills , Alex Krotulski , Paul Wax , On Behalf of the ToxIC DOTS Study Group","doi":"10.1016/j.drugalcdep.2025.112776","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Bromazolam, an illegal benzodiazepine, has recently increased in toxicological samples in the United States. Little is known about other substances detected with bromazolam and use intentions. This study investigated bromazolam’s prevalence, co-occurring substances, and self-reported substance use among patients with bromazolam exposure presenting to emergency departments (ED) for opioid/stimulant-related non-fatal overdose.</div></div><div><h3>Methods</h3><div>The Toxicology Investigators Consortium (ToxIC) Drug Overdose Toxico-Surveillance (DOTS) Reporting Program prospectively collected interviews, chart reviews, and toxicological blood analyses among patients presenting to one of 17 EDs following a suspected acute opioid/stimulant overdose. Toxicological analyses were performed qualitatively via liquid chromatography (LC) quadrupole time-of-flight mass spectrometry (MS) and quantitatively with LC tandem quadrupole MS. Sociodemographic characteristics, intended substance use, and detected substances were examined in patients with and without bromazolam exposure (n = 341).</div></div><div><h3>Results</h3><div>Twenty-eight of 341 patients (8.2 %) were bromazolam positive, with an average concentration of 86.4 <!--> <!-->ng/mL (range: 3.5–310.0 <!--> <!-->ng/mL). Fentanyl concentrations were higher among bromazolam-positive patients (positive: mean=11.1 <!--> <!-->ng/mL; negative: mean=8.9 <!--> <!-->ng/mL; <em>p</em> = 0.03), although no qualitative significant differences were noted in fentanyl prevalence when stratified by bromazolam exposure (<em>p</em> = 0.22). Among the 20 bromazolam-positive patients reported using only one substance, none intended to use bromazolam, with fentanyl (n = 7, 35.0%) and heroin (n = 6, 30.0%) being the most reported intended substances. Snorting was the most common administration route (55.0%).</div></div><div><h3>Conclusion</h3><div>Bromazolam exposure was associated with increased fentanyl concentrations compared to those without. Most patients with bromazolam exposure reported intended opioid use prior to their overdose. Future research should investigate bromazolam’s clinical effects and patient outcomes following an overdose.</div></div>","PeriodicalId":11322,"journal":{"name":"Drug and alcohol dependence","volume":"274 ","pages":"Article 112776"},"PeriodicalIF":3.6000,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug and alcohol dependence","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0376871625002297","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Bromazolam, an illegal benzodiazepine, has recently increased in toxicological samples in the United States. Little is known about other substances detected with bromazolam and use intentions. This study investigated bromazolam’s prevalence, co-occurring substances, and self-reported substance use among patients with bromazolam exposure presenting to emergency departments (ED) for opioid/stimulant-related non-fatal overdose.
Methods
The Toxicology Investigators Consortium (ToxIC) Drug Overdose Toxico-Surveillance (DOTS) Reporting Program prospectively collected interviews, chart reviews, and toxicological blood analyses among patients presenting to one of 17 EDs following a suspected acute opioid/stimulant overdose. Toxicological analyses were performed qualitatively via liquid chromatography (LC) quadrupole time-of-flight mass spectrometry (MS) and quantitatively with LC tandem quadrupole MS. Sociodemographic characteristics, intended substance use, and detected substances were examined in patients with and without bromazolam exposure (n = 341).
Results
Twenty-eight of 341 patients (8.2 %) were bromazolam positive, with an average concentration of 86.4 ng/mL (range: 3.5–310.0 ng/mL). Fentanyl concentrations were higher among bromazolam-positive patients (positive: mean=11.1 ng/mL; negative: mean=8.9 ng/mL; p = 0.03), although no qualitative significant differences were noted in fentanyl prevalence when stratified by bromazolam exposure (p = 0.22). Among the 20 bromazolam-positive patients reported using only one substance, none intended to use bromazolam, with fentanyl (n = 7, 35.0%) and heroin (n = 6, 30.0%) being the most reported intended substances. Snorting was the most common administration route (55.0%).
Conclusion
Bromazolam exposure was associated with increased fentanyl concentrations compared to those without. Most patients with bromazolam exposure reported intended opioid use prior to their overdose. Future research should investigate bromazolam’s clinical effects and patient outcomes following an overdose.
期刊介绍:
Drug and Alcohol Dependence is an international journal devoted to publishing original research, scholarly reviews, commentaries, and policy analyses in the area of drug, alcohol and tobacco use and dependence. Articles range from studies of the chemistry of substances of abuse, their actions at molecular and cellular sites, in vitro and in vivo investigations of their biochemical, pharmacological and behavioural actions, laboratory-based and clinical research in humans, substance abuse treatment and prevention research, and studies employing methods from epidemiology, sociology, and economics.